20250526-Bernstein-武田制药有限公司（4502）_武田制药_在应对美国政策难题的同时_专注于新产品推出（2024年第四季度投资者关系讨论后）_17页_787kb

Takeda Pharmaceutical Co Ltd Analysis Summary

• Rating and Price Target: Bernstein rates Takeda Market-Perform with a price target of JPY 4,500, based on DCF and P/E blended valuation. No major changes from previous model updates.

• US Market Dynamics: Takeda is actively mitigating US tariff risks (e.g., inventory building and supply chain adjustments) and expects limited FY2025 impact. The 340B and Medicare Part D redesign are expected to cause JPY130Bn in FY2025, with commercial insurance covering 60-70% of revenue due to products like Entyvio. MFN pricing could spill over to commercial products if Medicare/ Medicaid prices are lowered, but current ambiguity reduces immediate concerns.

• Efficiency Initiatives: To fund future growth, Takeda is cutting costs through workforce reductions (e.g., 3,000 headcount in FY2024), AI-driven sales tools, and procurement control. Savings are channeled into pipeline launches like rusfertide and oveporexton, with pre-launch preparations targeted at expanding market access.

• Financial Forecast: Revenue is expected to grow steadily, with EPS targets at JPY 491 for FY2024 and JPY 469 for FY2025. Gross margins are stable at around 65%, but tax increases from US international provisions may pressure net income. Free cash flow is positive, supporting investments.

• Investment Implications: Takeda's upside includes potential sales acceleration of Entyvio, while risks involve slowing revenue or regulatory setbacks. The Market-Perform rating reflects balanced outlook, with focus on navigating US policy changes and maintaining efficiency.